- Indivior said Friday it filed a new drug submission with Health Canada's Therapeutic Drugs Directorate for an opioid abuse treatment.

The move came after Health Canada granted priority review status for the treatment, Sublocade, on April 6. If the submission was approved, it would be marketed by Indivior Canada.

'A priority review designation indicates Health Canada's goal to review the new drug submission within a shortened target of 180 calendar days' the firm said. 'Indivior looks forward to working closely with regulatory authorities to ensure Sublocade, if approved, will be available as soon as possible to the Canadian treatment community to help address the current opioid public health crisis' said Shaun Thaxter, Chief Executive Officer of Indivior.

Story provided by